NCT06947941View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,046

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

September 27, 2027

Study Completion Date

October 25, 2027

Conditions
Alzheimer DiseasePsychosis
Interventions
DRUG

KarXT

Specified dose on specified days

DRUG

KarX-EC

Specified dose on specified days

DRUG

KarXT + KarX-EC Arm Matching Placebo

Specified dose on specified days

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06947941 - A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) | Biotech Hunter | Biotech Hunter